Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer

European Urology

Volumn 63, Issue 1, 2013, Pages 145-154

  Thomas, Francis ^a   Noon, Aidan P ^a   Rubin, Naomi ^a   Goepel, John R ^b   Catto, James W F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; CIS; High risk; Outcome; Prognosis

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA; CARCINOMA IN SITU; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENGLAND; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84870478251     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.064     Document Type: Article

References (16)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. K.D. Sievert, B. Amend, and U. Nagele Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27 2009 295 300
3. R.J. Sylvester, A.P. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477 discussion 475-7
4. J.W. Catto, A. Alcaraz, and A.S. Bjartell MicroRNA in prostate, bladder, and kidney cancer: a systematic review Eur Urol 59 2011 671 681
5. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
6. A. Stenzl, N.C. Cowan, and M. De Santis Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2011 1009 1018
7. G.S. Kulkarni, O.W. Hakenberg, and J.E. Gschwend An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer Eur Urol 57 2010 60 70
8. S. Van den Bosch, and J.A. Witjes Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review Eur Urol 60 2011 493 500
9. S.S. Alkhateeb, B.W. Van Rhijn, and A. Finelli Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumours J Urol 184 2010 81 86
10. J. Fernandez-Gomez, E. Solsona, and M. Unda Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials Eur Urol 53 2008 992 1002
11. F. Thomas, D.J. Rosario, N. Rubin, J.R. Goepel, M.F. Abbod, and J.W.F. Catto The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm? Cancer 118 2012 5525 5534
12. R.R. Hall, M.K. Parmar, A.B. Richards, and P.H. Smith Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy BMJ 308 1994 257 260
13. J.W. Catto, A. Hartmann, and R. Stoehr Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumour clearance J Urol 175 2006 2323 2330
14. Linton KD, Rosario DJ, Thomas F, et al. Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. J Urol. In press. http://dx.doi.org/10.1016/j.juro.2012.09.084.
15. B.W. Van Rhijn, L. Liu, and A.N. Vis Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer BJU Int 110 2012 1169 1176
16. F. Saint, L. Salomon, and R. Quintela Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature Eur Urol 43 2003 351 361 discussion 360-1